ArticleAnnals of surgical oncology2026
Association Between Axillary Surgical Management and Survival for Patients With De Novo Metastatic Breast Cancer.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe optimal management of the axilla in patients with de novo metastatic breast cancer (MBC) undergoing breast surgery remains unclear. This study aimed to evaluate the association between axillary surgical management and survival outcomes for patients with de novo MBC.
methodsThis retrospective single-center cohort study included patients with de novo extra-nodal MBC treated at Institut Curie between 2008 and 2019 and registered in the ESME database. Patients were categorized according to axillary management: axillary lymph node dissection (ALND) versus sentinel lymph node biopsy (SLNB) or no axillary surgery. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan-Meier methods. Inverse probability of treatment-weighting (IPTW) based on a propensity score was used to reduce selection bias.
resultsThe study included 246 patients including 182 (74%) who underwent ALND, 54 (21%) who received SLNB, and 10 (4%) who had no axillary surgery. After a median follow-up period of 60.3 months (95% confidence interval [CI], 55.9-64 months), axillary surgical management was not associated with survival outcomes. In IPTW-weighted analyses, ALND was not associated with better PFS than SLNB or no axillary surgery (hazard ratio [HR], 0.82; 95% CI, 0.53-1.25; p = 0.4), nor with improved OS (HR, 1.19; 95% CI, 0.64-2.25; p = 0.6). Patterns of disease progression were similar between the groups, with no increased nodal progression observed in the SLNB group.
conclusionFor patients with de novo MBC undergoing breast surgery, ALND was not associated with improved survival. These findings support a more conservative axillary approach for this population given the limited therapeutic benefit and potential morbidity of extensive axillary surgery.
Indexed as
Identifiers
42334720What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.